Evidence map›Paper›PMID 34067448›Full record

ReviewInternational journal of molecular sciences2021

Melatonin for Neonatal Encephalopathy: From Bench to Bedside.

Raymand Pang, Adnan Advic-Belltheus, Christopher Meehan, Daniel J Fullen, Xavier Golay, Nicola J Robertson

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Melatonin treatment for neonatal encephalopathy.The Cochrane database of systematic reviews · 2026
    Pooled it
  2. Efficacy of melatonin in term neonatal models of perinatal hypoxia-ischaemia.Annals of clinical and translational neurology · 2022
    Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Raymand PangInstitute for Women's Health, University College London, London WC1E 6HU, UK.ORCID 0000-0002-2004-6650
Adnan Advic-BelltheusInstitute for Women's Health, University College London, London WC1E 6HU, UK.
Christopher MeehanInstitute for Women's Health, University College London, London WC1E 6HU, UK.
Daniel J FullenTranslational Research Office, University College London, London W1T 7NF, UK.
Xavier GolayDepartment of Brain Repair and Rehabilitation, Institute of Neurology, University College London, London WC1N 3BG, UK.ORCID 0000-0002-6447-4446
Nicola J RobertsonInstitute for Women's Health, University College London, London WC1E 6HU, UK.
University College London · GB

Funding

Medical Research Council MR/M006743/1Medical Research Council MR/P025978/1
6 · The paper itself

Abstract

Neonatal encephalopathy is a leading cause of morbidity and mortality worldwide. Although therapeutic hypothermia (HT) is now standard practice in most neonatal intensive care units in high resource settings, some infants still develop long-term adverse neurological sequelae. In low resource settings, HT may not be safe or efficacious. Therefore, additional neuroprotective interventions are urgently needed. Melatonin's diverse neuroprotective properties include antioxidant, anti-inflammatory, and anti-apoptotic effects. Its strong safety profile and compelling preclinical data suggests that melatonin is a promising agent to improve the outcomes of infants with NE. Over the past decade, the safety and efficacy of melatonin to augment HT has been studied in the neonatal piglet model of perinatal asphyxia. From this model, we have observed that the neuroprotective effects of melatonin are time-critical and dose dependent. Therapeutic melatonin levels are likely to be 15-30 mg/L and for optimal effect, these need to be achieved within the first 2-3 h after birth. This review summarises the neuroprotective properties of melatonin, the key findings from the piglet and other animal studies to date, and the challenges we face to translate melatonin from bench to bedside.

Indexed as

AnimalsBrain DiseasesHumansHypothermia, InducedInfant, NewbornInfant, Newborn, DiseasesMelatoninNeuroprotectionNeuroprotective AgentsMelatoninNeuroprotective Agentshypoxia-ischaemiamelatoninneonatal encephalopathyneuroprotectiontherapeutic hypothermia

Identifiers

PMID34067448
PMCPMC8196955
OpenAlexW3164413225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.